<DOC>
	<DOCNO>NCT01980979</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Remodulin treatment adult patient congenital heart disease pulmonary hypertension . Baseline post-treatment cardiopulmonary exercise test perform .</brief_summary>
	<brief_title>Efficacy Remodulin Adults With Congenital Heart Disease ( ACHD ) Pulmonary Hypertension</brief_title>
	<detailed_description>A prospective , open-label , non-randomized multi-center study propose assess efficacy Remodulin adult congenital heart disease pulmonary hypertension . Subjects enrol UCLA Ohio State University ( PI : Curt Daniels , MD ) . The study involve six month trial continuous subcutaneous Remodulin therapy , assessment conduct prior initiation therapy 1 6 month follow initiation therapy . A separate initiation visit schedule baseline visit order provide subject comprehensive training use care Remodulin drug delivery system . Baseline post-treatment ( 6 month ) assessment include history physical examination , cardiopulmonary exercise test , six minute walk distance , serum brain natriuretic peptide ( BNP ) , Cambridge Pulmonary Hypertension Outcome Review ( CAMPHOR ) quality life survey , subjective assessment functional capacity ( New York Heart Association ( NYHA ) scale ) . The interim ( 1 month ) follow-up visit include thorough review adverse event associate Remodulin therapy , functional class assessment , six minute walk distance , serum BNP . Remodulin initiate 1.25 ng/kg/min increase 2-6 ng/kg/min weekly target dose 40 ng/kg/min . If initial infusion rate tolerate reduce 0.625 ng/kg/min . Changes drug dose discretion investigator follow review interim event . If necessary , dose may decrease 2 ng/kg/min every two day tolerate .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Age ≥ 18 year Congenital heart disease Pulmonary Arterial ( PA ) hypertension ( repair unrepaired ) define mean rest directly measure Pulmonary Artery Pressure ( PAP ) ≥35 mm Hg and/or doppler echo estimate PA systolic pressure ≥ 60 mm Hg . Patients already phosphodiesterase type 5 inhibitor ( PDE5 ) , Endothelin Receptor Antagonist ( ERA ) , inhaled prostacyclin exclude Age &lt; 18 year Current intravenous subcutaneous prostacyclin therapy Resting systemic hypotension ( Systolic blood pressure &lt; 80 mm Hg ) Women pregnant may become pregnant ( unwilling utilize effective contraception ) , well nurse mother Inability ambulate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>congenital heart disease , pulmonary hypertension , prostacyclin</keyword>
</DOC>